Inhibitory effect of tumor suppressor p33ING1b and its synergy with p53 gene in hepatocellular carcinoma

Zhi Zhu, Jing Lin, Jian-Hui Qu, Mark A. Feitelson, Can-Rong Ni, Fang-Mei Li, Ming-Hua Zhu

Zhi Zhu, Jing Lin, Jian-Hui Qu, Can-Rong Ni, Fang-Mei Li, Ming-Hua Zhu, Department of Pathology, Shanghai 200433, China. Mark A. Feitelson, Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA. Supported by the National Natural Science Foundation of China (Grants No.30070344 and No.30070839). Correspondence to: Ming-Hua Zhu, Department of Pathology, Shanghai 200433, China. mzhhu2000@hotmail.com

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

INTRODUCTION

Inhibitor of growth 1, ING1, is a newly cloned tumor suppressor[1], and appears to play a role in programmed cell death and cell cycle arrest, whereas antisense ING1 protects cells from apoptosis in various experimental systems. Ectopic expression of ING1 cDNA or ING1 suppression by antisense RNA demonstrates that ING1 is a negative regulator of cell proliferation[2-4]. ING1 protein has been reported to bind directly to p53 protein by immunoprecipitation in vitro, modulating the function of p53 as a transcription activator[5]. ING1 gene is mapped on human chromosome, 13q33-34, a region that has been implicated in the progression of various tumors[6,7]. Deregulated expression and mutation of ING1 gene are found in breast carcinoma, oral/esophageal squamous cell carcinoma, gastric carcinoma and malignant lymphomas, etc.[8,12-16]. It was also found that ING1 gene encodes several differentially initiated and spliced mRNAs, which have common 3'exon and encode at least two distinct proteins in mice, and possibly three distinct proteins in human cells (p47ING1a, p33ING1b, and p24ING1c). RT-PCR analysis showed that the ING1b form is a major transcript in human normal tissues. All the known ING1 protein isoforms share an identical C-terminal domain with a conserved PHD finger motif, which might directly interact with DNA[17,18,19].

HCC is one of the 10 most common cancers in the world and is almost uniformly fatal. The genetic events leading to the development of hepatocellular carcinoma are not well documented. Gene mutation and dysfunction of wild-type tumor suppressor p53 are important molecular events in the process of hepatocarcinogenesis[19-32]. p33ING1b has a close relationship with p53 and neither p53 nor p33ING1b alone can cause cell growth inhibition[20-22], which prompted us to investigate their potential role in hepatocellular carcinogenesis. We examined whether genetic mutation and altered protein expression of p33ING1b and p53 were responsible for the development and progression of human HCC.
MATERIALS AND METHODS

Materials

Human hepatoma cell lines HepG2, PLC/PRF/5, and Hep3B were maintained in Dulbecco’s MEM with 10% FCS (Hyclone), 2 mmol/L L-glutamine, and antibiotics at 37 °C in a 50 mL/L atmosphere. Plasmid pCI-ING1b (kindly provided by Dr. Karl Riabowol, Department of Medical Biochemistry, Calgary University, Canada) was digested with EcoRI/Xhol and Xhol/BamHI, and the resultant 900 bp fragment (ING1b cDNA full length) was ligated into the pcDNA3 vector (Invitrogen) containing the neomycin-resistance gene. This recombinant produced sense pcDNA3-p33ING1b plasmid (EcoRI/Xhol-digested) and antisense plasmid, pcDNA3-α p33ING1b (Xhol/BamHI-digested). Recombinant plasmids pCMV containing sense and antisense wild-type p53 gene were constructed in our laboratory (reported in other manuscripts, data not shown). Plasmid WPP-LUC containing the promoter of p21WAF1/CIP1 gene derived the expression of a luciferase reporter gene (kindly provided by Dr. B. Vogelstein, John Hopkins Oncology Center).

HCC and para-cancerous liver tissues were obtained from 57 patients with hepatocellular carcinoma who underwent surgery between 1997 and 2002 at the Department of Pathology, Changhai Hospital, Second Military Medical University. Twelve normal liver tissues were obtained from autopsies. All tissues were fixed in 10% formalin and paraffin-embedded.

Transient transfection

To determine the effects of p33ING1b and p53 gene upon the growth of hepatoma cells, 1×10⁶ cells of HepG2, PLC/PRF/5, and Hep3B were plated overnight and co-transfected by Lipofectamine 2000 (Gibco BRL) following the manufacturer’s instructions. The plasmids used in co-transfection were divided into four groups. HepG2 cells with endogenous wild-type p53 gene were transfected with 3 μg of pcDNA3-p33ING1b, pcDNA3-α p33ING1b, pcDNA3-p33ING1b + pCMV-α wtp53, respectively, and pcDNA3 vector alone as a control. PLC/PRF/5 cells with endogenous mutant p53 and Hep3B with endogenous p53 completely deleted were treated with 3 μg of pcDNA3-p33ING1b, pcDNA3-α p33ING1b + pCMV-wtp53, pcDNA3-p33ING1b + pCMV-wtp53, respectively, and pcDNA3 plain vector alone as control group. Cells were incubated overnight with the lipofectamine mix, then washed with PBS and maintained in complete medium.

Apoptosis and cell cycle arrest assay

Forty-eight hours after transfection, cell apoptosis was assayed using annexin V-FITC apoptosis detection kit (BD PharMingen, USA). Cells were collected, washed twice with cold PBS and resuspended in binding buffer (10 mmol/L Hepes/NaOH pH7.4, 140 mmol/L NaCl, 2.5 mmol/L CaCl₂, sterile filtered) at a concentration of 1×10⁶ cells/mL. One hundred microliters of the solution was transferred to a 5 mL culture tube, and 5 μL of annexin V-FITC and 5 μL of propidium iodide were added, then the cells were gently vortexed and incubated for 15 min at room temperature in the dark. Cell apoptosis was analyzed with FACSalibur.

CycleTEST plus DNA reagent kit (Becton Dickinson, CA) was applied to the cell cycle arrest assay. The number of each cell cycle phase was determined by FACSalibur following instructions of the manufacturer. All these assays were repeated at least twice.

Growth of HepG2-pcDNA3-p33ING1b, HepG2-pcDNA3-α p33ING1b, and HepG2-pcDNA3 in serum medium and soft agar

HepG2 cells were plated at 1×10⁶ cells per 100 mm dish and incubated overnight, then transfected with 3 μg of pcDNA3-p33ING1b, pcDNA3-α p33ING1b, respectively, and pcDNA3 vector alone as a control by lipofectamine 2000 (Gibco BRL). After transfection, the cells were selected in 800 μg/mL of G418 (Gibco BRL) for 3 wk. All resistant colonies were trypsinized and grown in complete medium. Resistant colonies of HepG2-pcDNA3-p33ING1b, HepG2-pcDNA3-α p33ING1b and HepG2-pcDNA3 cells were grown in complete medium and the number of viable cells was determined at daily intervals for 7 d after seeding. Cell viability was determined by trypsin blue staining. All experiments were constructed in triplicate, and the results were evaluated blindly. For growth in soft agar, 1×10⁴ cells/well were seeded in triplicate into six-well plates and allowed to grow for 21 d. The colonies were counted under a phase contrast microscope.

Luciferase assay

HepG2, PLC/PRF/5 and Hep3B cells were added to 24-well plates (1×10⁶ cells/well) and incubated overnight in complete medium, then cotransfected using lipofectamine method. The plasmids transfected into each cell line were the same as in the apoptosis assay but plus 0.2 μg of the reporter plasmid WPP-LUC and 10 ng of an internal control renilla luciferase plasmid, pS4V40 (Promega, Madison, WI) in each well. Cells were harvested 48 h after transfection. The activities of firefly and renilla luciferase were measured with a luminometer simultaneously using the dual-luciferase reporter assay kit (Promega) and normalized for the variation in transfection efficiency. All tests were done in triplicate.

Ethanol treatment

After transient transfection, the cells were treated with 60 mL/L ethanol in complete medium or PBS as control to induce apoptosis. Four hours after treatment, all cells (adherent or floating) were collected by trypsinization. Then apoptosis assay and luciferase assay were repeated again as described above. All tests were done in duplicate.

Immunohistochemistry

Protein staining of p33ING1b and p53 of 57 HCC and para-cancerous tissues was determined using EnVision method (DAKO). Histological sections (4-μm thick) on 0.02% poly-L-lysine coated slides (Sigma Chemical Co.) were deparaffinized and rehydrated, and the endogenous peroxidase activity was blocked by incubation with 2% H₂O₂ in phosphate buffer, followed by microwave antigen retrieval in citrate buffer (pH6.0). Nonspecific binding was blocked with goat serum, and sections were incubated with p33ING1b antibody and p53 antibody (clone DO-7, purchased from American antibody Corp. USA) overnight at 4 °C, respectively. Having washed
thrice to eliminate the residual antibody, the sections were incubated with EnVision complex. The reaction was developed by incubation with 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.), washed and counterstained with hematoxylin.

**Genomic DNA extraction and PCR-SSCP analysis**

Genomic DNA from 28 cases of HCC was isolated from paraffin-embedded tissues by SDS/protease K treatment. Genomic DNA extraction and PCR-SSCP analysis of HepG2 cells with endogenous wildtype p53 gene, the apoptosis rate of HepG2-pcDNA3-p33ING1b (22.53±1.4%) was significantly higher than those of other HepG2 experiment groups (P<0.01, Figures 1A-C). The proportion of HepG2-pcDNA3-p33ING1b cells arrested at G0/G1 phase (67.45±9.6%) was much more than cells transfected with vector or other control plasmids (P<0.05, Table 1). In addition, the apoptosis rate of HepG2 experiment groups was elevated, and the elevation extent was significantly higher than those of other HepG2 experiment groups (P<0.01, Figures 1A-C).

In PLC/PRF/5 cells with endogenous mutant p53, the difference in apoptosis rate between cells cotransfected with pcDNA3-p33ING1b and pCMV-wtp53 (42.8±1.3%) was significantly higher than that of other HepG2 experiment groups (P<0.05). After 6% ethanol treatment, apoptosis of all PLC/PRF/5 experiment groups was elevated, and the elevation extent of HepG2-pcDNA3-p33ING1b was the most significant (48.92±1.6%, P<0.01, Figures 1A-C).

**RESULTS**

**Drastically enhanced apoptosis and G0/G1 arrest in hepatoma cells by synergy of p33ING1b with p53**

In HepG2 cells with endogenous wildtype p53 gene, the apoptosis rate of HepG2-pcDNA3-p33ING1b (22.53±1.4%) was significantly higher than those of other HepG2 experiment groups (P<0.01, Figures 1A-C). The proportion of HepG2-pcDNA3-p33ING1b cells arrested at G0/G1 phase (67.45±9.6%) was much more than cells transfected with vector or other control plasmids (P<0.05, Table 1). In addition, the apoptosis rate of HepG2 experiment groups was elevated, and the elevation extent of HepG2-pcDNA3-p33ING1b was the most significant (48.92±1.6%, P<0.01, Figures 1A-C).

In PLC/PRF/5 cells with endogenous mutant p53, the difference in apoptosis rate between cells cotransfected with pcDNA3-p33ING1b and pCMV-wtp53 (7.81±0.3%) and control plasmid was not significant (P>0.05). After 6% ethanol treatment, apoptosis of all PLC/PRF/5 experiment groups was enhanced. The apoptosis rate of cotransfection with p33ING1b and wtp53 (42.8±1.3%) was significantly higher than that of other groups (P<0.01). In addition, the apoptosis induced by cotransfection with p33ING1b and wtp53 (1.59±0.2%) in Hep3B cells without endogenous p53 was statistically significant.

**Statistical analysis**

The relationship between p33ING1b and p53 protein positive staining was evaluated using Wilcoxon signed rank test. The growth difference of HepG2-p33ING1b and HepG2-α p33ING1b in soft agar was analyzed by Student’s t-test. All data were represented as mean±SD. P<0.05 was considered statistically significant.

**Figure 1** FACS analysis of cell apoptosis in three hepatoma cell lines (A-C) and arrest of HepG2 cells at G0/G1 cell cycle (D-G).
HepG2 cells stably transfected with pcDNA3-p33ING1b in soft agar (1.59±0.2%) was significantly lower than that in HepG2-pcDNA3-p33ING1b group, but the difference in apoptosis rate between each experiment group of Hep3B was not significant (P>0.05). After 6% ethanol treatment, the difference was still not significant although the apoptosis rate of each Hep3B experiment group had a slight increase (Figure 1A-C). The proportion of PLC/PRF/5 cells cotransfected with p33ING1b and wtp53 arrest at GO/G1 phase (78.16±10.6%) was significantly higher than those in other control groups (P<0.05), but the difference between each Hep3B experiment group was not significant (P>0.05, Table 1).

Overexpression of p33ING1b inhibited hepatocellular growth and survival
The growth curve of HepG2 cells showed that HepG2-pcDNA3-p33ING1b cells grew significantly slower than HepG2-pcDNA3 and HepG2-pcDNA3-α p33ING1b cells (P<0.01, Figure 2). Additional experiments were conducted to test whether p33ING1b overexpression correlated with anchorage-independent growth in soft agar. Results showed that the growth in soft agar of HepG2-pcDNA3-p33ING1b cells with p33ING1b overexpression was inhibited compared with that of HepG2-pcDNA3 cells (P<0.01). However, HepG2 cells stably transfected with pcDNA3-α p33ING1b significantly promoted the anchorage-independent growth in soft agar (P<0.01, Table 1).

Synergistic effect of p33ING1b with p53 on activating p53 downstream gene, p21WAF1/CIP1
The results of luciferase assay showed that the activity of p21WAF1/CIP1 promoter in HepG2-pcDNA3-p33ING1b (13.81±1.0), or PLC/PRF/5 (12.99±1.1) and Hep3B cells (10.32±0.6) cotransfected with p33ING1b and wtp53 genes was significantly stronger than that in control cells transfected with insert-free vector (3.027±0.4) (P<0.01). Whereas after transfection with antisense-p33ING1b and antisense-wtp53 plasmids, the activity of p21WAF1/CIP1 promoter activated by p33ING1b or p53 gene alone was significantly lower than that activated by p33ING1b and p53 in combination (P<0.01), and similar to that activated by transfection with plain vector (P>0.05). After 6% ethanol treatment, the activity of p21WAF1/CIP1 promoter was elevated in all experiment groups, especially in HepG2-pcDNA3-p33ING1b (17.82±0.8), Hep3B and PLC/PRF/5 cells cotransfected with p33ING1b and wtp53 genes (18.12±1.0 and 16.82±0.7, respectively) (P<0.01, Figure 3). These results indicate that the function of p53 as a transcriptional activator depends on the presence of p33ING1b, and the synergistic action of p33ING1b with p53 might enhance the activation of p21WAF1/CIP1.

Expression of p33ING1b and p53 and mutation analysis of p33ING1b gene in HCC
Immunohistochemistry results revealed that both p33ING1b

| Cell line | Transfection plasmids | G0/G1 arrest |
|-----------|------------------------|--------------|
| HepG2     | p33ING1b               | 67.45±9.6    |
|           | op33ING1b              | 53.45±10.1   |
|           | p33ING1b-αwtp53        | 55.61±8.3    |
|           | pcDNA3                 | 58.78±10.3   |
| PLC/PRF/5 | p33ING1b               | 64.79±11.1   |
|           | p33ING1b-αwtp53        | 78.16±10.5   |
|           | op33ING1b-α wtp53      | 60.17±9.8    |
|           | pcDNA3                 | 56.56±8.8    |
| Hep3B     | p33ING1b               | 48.90±7.6    |
|           | p33ING1b-αwtp53        | 55.91±10.1   |
|           | op33ING1b-α wtp53      | 50.92±8.5    |
|           | pcDNA3                 | 52.87±7.0    |

*p<0.05; **p<0.01, and ***p<0.01 vs the control groups.

| Experiment | Number of colonies | Caspase activity |
|------------|--------------------|------------------|
|            |                    | C57              |
|            |                    | 1                |
|            |                    | 2                |
|            |                    | 3                |

*p and **p<0.01, vs HepG2-pcDNA3 control.

| Table 2 Cloning efficiency of HepG2 cells after transfection of sense and antisense p33ING1b gene (mean±SD) |
|---------------------------------------------------------------|
| Experiment                  | Number of colonies | Caspase activity |
|-----------------------------|--------------------|------------------|
| HepG2-p33ING1b              | 65±7               | 1                |
| HepG2-op33ING1b             | 149±12             | 2                |
| HepG2-pcDNA3                | 86±9               | 3                |
| Hep3B                       | 68±15              | 4                |
| PLC/PRF/5                   | 151±10             | 5                |
| HepG2-pcDNA3                | 93±11              | 6                |
| HepG2-op33ING1b             | 148±11             | 7                |
| HepG2-pcDNA3                | 94±10              | 8                |

Note: Staining was estimated as follows: -, negative; +, weak; ++, intermediate; ++++, strong positive staining.

Figure 2 Growth curves for HepG2 cells stably transfected with pcDNA3 (▲), pcDNA3-p33ING1b (●), or pcDNA3-α p33ING1b (■) in complete medium containing 10% serum.
and p53 proteins were all nuclear positive in paraffin-embedded tissues from 57 cases of HCC. The positive rate of p33ING1b and p53 was 42.1% and 57.9%, respectively. Both had the same positive localization in HCC tissues, and their expression had a positive correlation (Wilcoxon test, \( r = 0.783, P < 0.01 \)). In 13 out of 51 para-cancerous liver tissues and 2 out of 12 normal liver tissues, p33ING1b protein presented weak staining, whereas p53 protein was negative in all para-cancerous liver tissues and normal liver tissues (Table 3 and Figure 4).

No aberrant PCR-amplification products were found in tumor and para-cancerous tissues compared with normal liver tissues, suggesting that ING1b gene did not have a fragmental frame shift or more than a dozen of base pairs deletion in HCC. Five HCC cases presenting abnormal band shifting were identified by SSCP, two of them showed a G to C transversion at the middle nucleotide of codon 215 with an amino change in ING1b gene exon2 by DNA sequencing, resulting in a cysteine to serine substitution. p33ING1b gene did not exhibit mutation in para-cancerous tissues. All the point mutations were confirmed by repeated PCR amplification and sequencing from both ends (Figure 5).

The frequency of missense mutation of the ING1b gene in HCC was low (7.1%). Our results were consistent with those of head and neck squamous cell carcinoma (13%) reported by Gunduz et al[18], and esophageal squamous cell carcinoma (12.7%) reported by Chen et al[16].

**DISCUSSION**

Ectopic expression of the first isolated human ING1 cDNA is growth-suppressive in different cell lines[6-8]. One of the reasons why this gene has gained increasing attention from the biological community is that it has no structural similarity with p53, but has many tumor suppressive functions including growth arrest, apoptosis, senescence and sensitization to drug treatment. p33ING1b, one of the alternative transcripts of ING1 gene, is physically associated with p53, further proving its role in carcinogenesis[8-9]. As an important member of p53-interacting proteins family, p33ING1b inactivation

---

**Figure 3** Analysis of p21^{WAF1/CIP1} promoter activation in three hepatoma cell lines.

**Figure 4** IHC staining for p33ING1b on HCC (A), para-cancerous tissues (B), and normal liver tissues (C), and for p53 on HCC (D). A and D: p33ING1b and p53 were nuclear-positive and located in the same area of HCC, \( \times 400 \); B and C: p33ING1b presented weak IHC staining, \( \times 200 \).
might be another critical reason for the loss of tumor suppressive function of p33\textsuperscript{ING1b} in HCC. Moreover, the tumor suppressive activity of p33\textsuperscript{ING1b} requires an intact p53 gene, neither of these two genes can inhibit tumor cell growth when one of them is suppressed\textsuperscript{[26,27,30]}.

We found that overexpression of p33\textsuperscript{ING1b} inhibited the growth of HepG2 cells and suppressed the cell anchorage-independent survival in soft agar, which is consistent with the tumor-suppression role of p33\textsuperscript{ING1b} in the development of HCC. However, the synergic effects of p33\textsuperscript{ING1b} and p53 on apoptosis and cell cycle arrest in hepatoma cell lines have not been well established. In this study, overexpression of p33\textsuperscript{ING1b} effectively inhibited the growth of hepatoma cells and protected cells from malignant transformation; cointraduction of p33\textsuperscript{ING1b} and p53 enhanced apoptosis of hepatoma cells, arrested more cells at G\textsubscript{0}/G\textsubscript{1} phase and elevated the expression of p21\textsuperscript{WAF1/CIP1} gene compared with the introduction of either p33\textsuperscript{ING1b} or p53 gene alone; the expression of p33\textsuperscript{ING1b} and p53 proteins had a close relation and exhibited the same positive staining localization in HCC; p33\textsuperscript{ING1b} gene had a low mutation rate (7.1%) in HCC. These results suggest that p33\textsuperscript{ING1b} plays an important role in refraining the process of hepatocarcinogenesis and the cooperation of p33\textsuperscript{ING1b} and p53 is essential to normal biological functions of these two genes\textsuperscript{[26-30]}. However, this cooperation in hepatoma cells might be influenced by other factors such as HBV infection or Rb gene deletion.

There is evidence that HBV X antigen is capable of binding to wild-type p53 protein, leading to p53 inactivation and accumulation in HBV-infected liver cells, which influence the result in HBV-associated hepatocarcinogenesis\textsuperscript{[22,27,32]}, p33\textsuperscript{ING1b} protein also binds to p53 protein and forms a complex in vivo. It is hypothesized that HBxAg may interact with p53-p33\textsuperscript{ING1b} protein complex and influence the biological synergy of p33\textsuperscript{ING1b} with p53. After cotransfection of p33\textsuperscript{ING1b} and p53 into PLC/PRF/5 or Hep3B cells infected with HBV, apoptosis and G\textsubscript{0}/G\textsubscript{1} arrest are elevated, but the extent is not as significant as that in HepG2 cells without HBV infection\textsuperscript{[23]}. These results suggest that HBV may play an important role in repressing the cooperation of p33\textsuperscript{ING1b} with p53. Whether HBV can directly bind to p33\textsuperscript{ING1b} protein and the mechanism of HBV inactivating p33\textsuperscript{ING1b} remain to be studied.

Tumor suppressors contribute to the regulation of mammalian cell cycle and apoptosis, largely through interaction with multiple proteins, which form a complex gene network\textsuperscript{[28,33]}. P33\textsuperscript{ING1b} is an important member of p53-related gene network, and other downstream genes may influence the synergy of p33\textsuperscript{ING1b} with p53. It is interesting that in Hep3B cells with HBV infection and endogenous Rb gene complete deletion\textsuperscript{[22]}, apoptosis and cell cycle arrest induced by combined transfection of p33\textsuperscript{ING1b} and p53 gene are much lower than those in HepG2 and PLC/PRF/5 cells, suggesting that loss of normal function of other important genes, such as Rb gene, may be a potential mechanism for inactivation of p33\textsuperscript{ING1b} and its cooperation with p53.

The data from other laboratories demonstrate that overexpression of p33\textsuperscript{ING1b} in human fibrosarcoma cell lines containing endogenous wild-type p53 greatly increases cell sensitivity to DNA damage caused by chemotherapeutic drug etoposide or \textgamma{} irradiation\textsuperscript{[18]}. Our study showed that combined transfer of p33\textsuperscript{ING1b} and p53 enhanced cell sensitivity to ethanol, rendered more cell apoptosis and arrested in G\textsubscript{0}/G\textsubscript{1} phase, and strongly activated the expression of downstream gene p21\textsuperscript{WAF1/CIP1}, suggesting that the synergy of p33\textsuperscript{ING1b} with p53 may enhance the tumor-suppressing effect of chemotherapy on HCC.

Although the sequence of ING1 gene is not altered frequently, previous study also noted the presence of p33\textsuperscript{ING1b} gene mutation in head and neck squamous cell cancer (HNSCC)\textsuperscript{[18]} and esophageal squamous cell cancer (SCC)\textsuperscript{[16]}, which are similar to our HCC results. There is accumulating evidence that gene mutation is not the main mechanism of biological inactivation of p33\textsuperscript{ING1b} in HNSCC\textsuperscript{[18]}. Many studies have shown that p33\textsuperscript{ING1b} protein is downregulated in other cancers such as breast cancer, gastric and colon cancer, malignant lymphoma, but methylation of the ING1 promoter region occurs in HNSCC\textsuperscript{[16]}. ING1 gene may serve as a “class II tumor suppressor” being inactivated at the level of RNA rather than DNA\textsuperscript{[16,18]}. As p33\textsuperscript{ING1b} and p53 have a close cooperation, low expression of p33\textsuperscript{ING1b} protein may be a mechanism underlying the inactivation of wild-type p53 in these cancers. Immunostaining in this study showed that p33\textsuperscript{ING1b} and p53 had a positive relation in HCC tissues and both had the same nuclear localization. Cells positive for p53 staining can express mutant p53 protein because of its prolonged half-life, and cells expressing wild-type p53 protein are usually negative for p53 staining. Our results demonstrate that p33\textsuperscript{ING1b} might also have a close relation with mutant p53 and wtp53. It is still not clear which domain of p53 protein binds to p33\textsuperscript{ING1b} protein. If mutation does not locate in the interaction domain of p53, physical interaction between p33\textsuperscript{ING1b} and p53 proteins would not be affected. Whether p33\textsuperscript{ING1b} binds to mutant p53 still has normal biological functions needs further study.

In conclusion, p33\textsuperscript{ING1b} cooperates with p53 in inhibiting hepatoma cell growth. Whether the interaction between these two genes occurs at other levels such as at p53 DNA binding level or p53 nuclear transport needs further investigation. The involvement of p33\textsuperscript{ING1b} in p53 signaling pathway indicates that p33\textsuperscript{ING1b} is essential for p53 function, loss or inactivation of p33\textsuperscript{ING1b} may contribute to malignant transformation of HCC retaining wild-type p53.
ACKNOWLEDGEMENTS

The authors thank Dr. Ribavkolov K. for his generous gifts of p33ING1 monoclonal antibody and pCI-ING1b plasmid and Dr. Vogelstein B for plasmid WWP-LUC.

REFERENCES

1. Garkavtsev I, Kazarov A, Gudkov A, Ribavkolov K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet 1996; 14: 415-420
2. Ma D, Lawless D, Ribavkolov K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation (correction). Nat Genet 1999; 23: 273
3. Garkavtsev I, Ribavkolov K. Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Mol Cell Biol 1997; 17: 2014-2019
4. Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Ribavkolov K. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res 2002; 62: 4445-4452
5. Garkavtsev I, Grigorian I.A., Osovskaya VS, Chernov MV, Chumakov PM, Gudkov AV. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998; 391: 295-298
6. Zerevski M, Horrigan SK, Grigorian I.A., Westbrook CA, Gudkov AV. Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. Somat Cell Mol Genet 1997; 23: 233-236
7. Garkavtsev I, Demetric D, Ribavkolov K. Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene [ING1]. Cytogenet Cell Genet 1997; 76: 176-178
8. Sanchez-Cespedes M, Okami K, Cairns P, Siddranys D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosomes Cancer 2000; 27: 319-322
9. Oki E, Maehara Y, Tokunaga E, Kakeji Y, Ohno S, Sugimachi K. Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett 1997; 147: 157-162
10. Sarela AI, Farmery SM, Markham AF, Guillou PJ. The candidate tumor suppressor gene, ING1, is retained in colorectal carcinomas. Eur J Cancer 1999; 35: 1264-1267
11. Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Ribavkolov K. Suppression of ING1 expression in sporadic breast cancer. Oncogene 1999; 18: 5187-5193
12. Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S, Sugimachi K. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett 2000; 152: 15-22
13. Ohmori M, Nagai M, Tasaka T, Koeffer HP, Toyama T, Ribavkolov K, Takahara J. Decreased expression of p33ING1 mRNA in lymphoid malignancies. Am J Hematol 1999; 62: 118-119
14. Ito K, Kinjo K, Nakazato T, Ikeda Y, Kizaki M. Expression and sequence analyses of p33(ING1) gene in myeloid leukemia. Am J Hematol 2002; 69: 141-143
15. Nouman GS, Anderson JJ, Wood KM, Lunec J, Hall AG, Reid MM, Angus B. Loss of nuclear expression of the p33(ING1) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002; 55: 596-601
16. Chen L, Matsuba N, Yoshino T, Nagasaka T, Tsuchiya M, Shirakawa Y, Naotomo Y, Iozaki H, Ribavkolov K, Tanaka N. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res 2001; 61: 4345-4349
17. Zerevski M, Hill JE, Kweek SS, Grigorian I.A., Gurova KV, Garkavtsev I, Darienko L, Koomin EV, Gudkov AV. Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. J Biol Chem 1999; 274: 32172-32181
18. Gunduz M, Ouchiha M, Fukushima K, Hanafusa H, Etani T, Nishioha S, Nishizaki K, Shimizu K. Genomic structure of the human ING1 gene and tumor specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 2000; 60: 3143-3146
19. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A, Harris CC. Integrity of p53 in hepatitis B x antigen- positive and negative hepatocellular carcinomas. Cancer Res 1997; 57: 426-432
20. Boland D, Olineek V, Bonnet J-P, Vieyra D, Parr E, Ribavkolov K. A panel of CAB antibodies recognize endogenous and ectopically expressed ING1 protein. Hybridoma 2000; 19: 161-165
21. Garkavtsev I, Boland D, Mai J, Wilson H, Veillette C, Ribavkolov K. Specific monoclonal antibody raised against the p33ING1 tumor suppressor. Hybridoma 1997; 16: 537-540
22. Puisieux A, Galvin K, Troalen F, Bressac B, Marcail C, Galun E, Ponchal F, Yakici C, Ji J, Ozturk M. Retinoblastoma and p53 tumor suppressor genes in human hematopoietic cell lines. FASEB J 1993; 7: 1407-1413
23. Hui AM, Kaniy S, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-579
24. Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 2000; 19: 468-471
25. Shinoura N, Muramatsu Y, Nishimura Y, Saito A, Yokoyama T, Furukawa T, Hori A, Hashimoto M, Asai A, Kiriho T, Hamada H. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 1999; 59: 5521-5528
26. Helbing CC, Veillette C, Ribavkolov K, Johnston RN, Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res 1997; 57: 1255-1258
27. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310
28. Ohgi T, Masaki T, Nakai S, Morishita A, Yukimasa S, Nagai M, Miyauchi Y, Funaki T, Turokohchi K, Watanabe S, Kuriyama S. Expression of p33(ING1) in hepatocellular carcinoma: relationships to tumour differentiation and cyclin E kinase activity. Scand J Gastroenterol 2002; 37: 1440-1448
29. Zhu Z, Zhu M, Ni C. Significance of p33(ING1b) and p53 gene expression in hepatocellular carcinoma. Zhonghua Yixue Za Zhi 2002; 82: 1332-1336
30. Zhu Z, Lin J, Qu JH, Li FM, Ni CR, Zhu MH. Study of cooperation of tumor suppressor p33(ING1b) with p53 gene in hepatocellular carcinoma. Zhonghua Bingli Zhi Za Zhi 2003; 32: 43-47
31. Lin J, Zhu MH, Zhu S, Qu JH, Li FM, Ni CR. The role of hepatitis B virus X gene and p53 on hepatocellular carcinoma cell growth. Zhonghua Bingli Xue Za Zhi 2003; 32: 43-47
32. Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Ribavkolov K. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res 2002; 62: 4445-4452
33. Nouman GS, Anderson JJ, Wood KM, Lunec J, Hall AG, Reid MM, Angus B. Loss of nuclear expression of the p33(ING1) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002; 55: 596-601
34. Vieyra D, Loeweth R, Scott B, Monnepin F, Boisvert FM, Cheema P, Paski Jasa S, Meijer M, Johnston RN, Bazett-Jones DP, McManus S, Cole MD, Young D, Ribavkolov K. Human ING1 proteins differentially regulate histone acetylation. J Biol Chem 2002; 277: 29832-29839
35. Nouman GS, Angus B, Lunec J, Crosier S, Lodge A, Anderson JJ. Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybridomics 2001; 20: 1-10
36. Campos EL, Cheung KJ, Murray A, Li S, Li G. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines. Br J Dermatol 2002; 146: 574-580

Science Editor Wang XL and Guo SY Language Editor Elsevier HK